BOTHELL, Wash.--(BUSINESS WIRE)--Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced that it has been granted four new U.S. and foreign patents, further strengthening the company’s intellectual property assets. The patents focus on dermatological health, where the company continues to build its industry leading intellectual property portfolio. The patents include:
•U.S. patent number 8,071,555 B2, entitled “Protective Skin Care Peptides”; •European patent number 2027152, entitled “Peptide Fragments for Inducing Synthesis of Extra Cellular Matrix Proteins.
